Genomic Vision Launches “GV STORE” Online Store to Support Sales of Product from LSR Activities
27 Juin 2017 - 8:30AM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of diagnostic solutions for the
early detection of cancers and serious genetic diseases and tools
for life sciences research, today announced it has launched a new
commercial website, the GV Store, to enable its global client base
to order products and services of LSR activities directly
on-line.
“In order to address the high demand of our LSR solutions, in
particular in international markets where we realize 90% of our
sales, it was essential to propose our customers a simple and fast
process of order taking and administrative follow. Thanks to GV
Store we are extremely confident as for the long-lasting
acceleration of our sales of products and services. While reducing
delays of delivery, this e-commerce site comes to strengthen the
added value of our technologies with life science research labs,”
commented David Del Bourgo, Marketing and Sales Director of
Genomic Vision.
Genomic Vision offers the Molecular Combing platform, a
technology that enables the detection of structural variations in
the genome and analyzes dynamics parameters such as DNA
replication. The company sells equipment, reagents and services
directly to clients in Europe, the US and through distributors in
China. Genomic Vision’s clients vary from clinical and academics
laboratories, to biotechnology and pharmaceutical companies.
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong technology allowing to identify
genetic abnormalities, GENOMIC VISION stimulates the R&D
productivity of the pharmaceutical companies, the leaders of the
diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests
(breast, ovarian and colorectal cancers, myopathies) and analysis
tools (DNA replication, biomarkers discovery, gene editing quality
control). Based near Paris, in Bagneux, the Company has
approximately 60 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV - ISIN: FR0011799907). For further information,
please visit www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626006269/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorMilestonesPress
RelationsBruno Arabian, +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel Huynh, +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024